ISSN: 1838-7640Theranostics
- Current issue
- Volume 14; 2024
- Volume 13; 2023
- Volume 12; 2022
- Volume 11; 2021
- Volume 10; 2020
- Archive
- Advance articles
- Cover images
- Index & coverage
- Cover suggestion
- Special issues
Nanotheranostics 2024; 8(4): 442-457. [Abstract] [Full text] [PDF]
Nanotheranostics 2024; 8(4): 427-441. [Abstract] [Full text] [PDF]
International Journal of Biological Sciences
International Journal of Medical Sciences
Global reach, higher impact
Theranostics 2022; 12(7):3079-3083. doi:10.7150/thno.71788 This issue Cite
Editorial
Theranostics approach in drug development: is there study efficiency when the prevalence of the molecular target is very high?
1. Division of Biometrics I, Office of Biostatistics, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration.
2. Division of Imaging and Radiation Medicine, Office of Specialty Medicine, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration.
Citation:
Wang SJ, Fotenos A, Masters SC, Marzella L. Theranostics approach in drug development: is there study efficiency when the prevalence of the molecular target is very high?. Theranostics 2022; 12(7):3079-3083. doi:10.7150/thno.71788. https://www.thno.org/v12p3079.htm
Other styles
Citation styles
APA
Wang, S.J., Fotenos, A., Masters, S.C., Marzella, L. (2022). Theranostics approach in drug development: is there study efficiency when the prevalence of the molecular target is very high?. Theranostics, 12(7), 3079-3083. https://doi.org/10.7150/thno.71788.
ACS
Wang, S.J.; Fotenos, A.; Masters, S.C.; Marzella, L. Theranostics approach in drug development: is there study efficiency when the prevalence of the molecular target is very high?. Theranostics 2022, 12 (7), 3079-3083. DOI: 10.7150/thno.71788.
NLM
Wang SJ, Fotenos A, Masters SC, Marzella L. Theranostics approach in drug development: is there study efficiency when the prevalence of the molecular target is very high?. Theranostics 2022; 12(7):3079-3083. doi:10.7150/thno.71788. https://www.thno.org/v12p3079.htm
CSE
Wang SJ, Fotenos A, Masters SC, Marzella L. 2022. Theranostics approach in drug development: is there study efficiency when the prevalence of the molecular target is very high?. Theranostics. 12(7):3079-3083.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
